Quanto si può vivere con la fibrillazione atriale

Riferimenti

1. Lip GYH, et al. (2016) Atrial Fibrillation. Nature Reviews, Disease Primers. Vol. 2. doi:10.1038/nrdp.2016.16 . Published online 31 March 2016. 2. Global Burden of Disease Collaborative Network (2016) Global Burden of Disease Study 2016 (GBD 2016) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2017. Accessed 2018-04-20. Available from http://ghdx.healthdata.org/gbd-results-tool. 3. Thrall G, Lane D, Carroll D, Lip GY (2006) Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 119 (5): 448.e441-419. 4. Dorian P, Jung W, Newman D, Paquette M, Wood K et al. (2000) The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 36 (4): 1303-1309. 5. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al. (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. Bmj 354 i4482. 6. Boriani G, Proietti M (2017) Atrial fibrillation prevention: an appraisal of current evidence. Heart (0):1–6. 7. van den Berg MP, Hassink RJ, Tuinenburg AE, van Sonderen EF, Lefrandt JD et al. (2001) Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J 22 (3): 247-253. 8. Roalfe AK, Bryant TL, Davies MH, Hackett TG, Saba S et al. (2012) A cross-sectional study of quality of life in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation Treatment of the Aged study. Europace 14 (10): 1420-1427. 9. Dudink E, Erkuner O, Berg J, Nieuwlaat R, de Vos CB et al. (2017) The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. Europace. 10. Aliot E, Botto GL, Crijns HJ, Kirchhof P (2014) Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace 16 (6): 787- 796. 11. Oliva-Moreno J, Pena-Longobardo LM, Mar J, Masjuan J, Soulard S et al. (2018) Determinants of Informal Care, Burden, and Risk of Burnout in Caregivers of Stroke Survivors: The CONOCES Study. Stroke 49 (1): 140-146. 12. Chen SY, Vanderpoel J, Mody S, Nelson WW, Schein J et al. (2012) Caregiver assistance among Medicare beneficiaries with atrial fibrillation and factors associated with anticoagulant treatment. Am J Geriatr Pharmacother 10 (5): 273-283. 13. Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS et al. (2015) The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review. Eur J Cardiovasc Nurs 14 (2): 98-107. 14. Coleman CI, Coleman SM, Vanderpoel J, Nelson W, Colby JA et al. (2012) Factors associated with ‘caregiver burden’ for atrial fibrillation patients. Int J Clin Pract 66 (10): 984-990. 15. Lo Buono V, Corallo F, Bramanti P, Marino S (2017) Coping strategies and health-related quality of life after stroke. J Health Psychol 22 (1): 16-28. 16. Burn J, Dennis M, Bamford J, Sandercock P, Wade D et al. (1994) Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 25 (2): 333-337. 17. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A et al. (2010) Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 29 (1): 43-49. 18. Andrew NE, Thrift AG, Cadilhac DA (2013) The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology 40 (4): 227-239. 19. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (38): 2893-2962. 20. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M et al. (2018) Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 21. Nazli C, Kahya Eren N, Yakar Tuluce S, Kocagra Yagiz IG, Kilicaslan B et al. (2016) Impaired quality of life in patients with intermittent atrial fibrillation. Anatol J Cardiol 16 (4): 250-255. 22. Aliot E, Botto GL, Crijns HJ, Kirchhof P (2014) Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace 16 (6): 787- 796. 23. Serpytis R, Navickaite A, Serpytiene E, Barysiene J, Marinskis G et al. (2018) Impact of Atrial Fibrillation on Cognitive Function, Psychological Distress, Quality of Life, and Impulsiveness. Am J Med. 24. Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y (2014) Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 133 (4): 550-554. 25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (12): 1139-1151.  26. Rocket AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159 (3): 340-347 e341. 27. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD et al. (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (22): 2093-2104. 28. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (11): 981-992. 29. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA et al. (2015) Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 17 (12): 1747-1769. 30. Suarez Fernandez C, Castilla-Guerra L, Cantero Hinojosa J, Surinach JM, Acosta de Bilbao F et al. (2018) Satisfaction with oral anticoagulants in patients with atrial fibrillation. Patient Prefer Adherence 12 267-274. 31. Ynsaurriaga FA, Peinado RP, Ormaetxe Merodio JM (2014) Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiol 10 (3): 381-393. 32. Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, D'Ambrosio G et al. (2013) Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol 111 (5): 705-711.